Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Growth-hormone and prolactin excess

A Colao¹, G Lombardi

¹Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy. rpivone@tin.it

Lancet (London, England)

|November 10, 1998

Summary

New long-acting medications for acromegaly and hyperprolactinaemia, including cabergoline, offer improved treatment options. These advanced therapies benefit patients with poor responses or intolerance to older drugs, improving associated health risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.

Endocrine·2026

Same author

The management of adrenocortical carcinoma in the era of precision medicine.

Critical reviews in oncology/hematology·2025

Same author

Nutritional assessment and medical dietary therapy for management of obesity in patients with non-dialysis chronic kidney disease: a practical guide for endocrinologist, nutritionists and nephrologists. A consensus statement from the Italian society of endocrinology (SIE), working group of the club nutrition-hormones and metabolism; the Italian society of nutraceuticals (SINut), club ketodiets and nutraceuticals "KetoNut-SINut"; and the Italian society of nephrology (SIN).

Journal of endocrinological investigation·2024

Same author

Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.

Journal of endocrinological investigation·2024

Same author

Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism.

Journal of endocrinological investigation·2024

Same author

Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.

Journal of endocrinological investigation·2024

Area of Science:

Endocrinology
Pharmacology

Background:

Acromegaly and hyperprolactinaemia present significant health challenges.
Previous treatments had limitations in efficacy and tolerability.

Purpose of the Study:

To review advancements in pharmacotherapy for acromegaly and hyperprolactinaemia.
To highlight the benefits of newer long-acting medications.

Main Methods:

Review of current pharmacological treatments.
Analysis of efficacy and tolerability of somatostatin analogues and dopamine agonists.

Main Results:

Slow-release somatostatin analogues and long-acting dopamine agonists (e.g., cabergoline) offer effective and well-tolerated treatment.
These newer agents improve outcomes for patients previously refractory or intolerant to older drugs (e.g., octreotide, bromocriptine).
Improved disease management has led to partial reversal of comorbidities like cardiomyopathy and sleep apnoea.

Conclusions:

Modern pharmacotherapy has significantly enhanced the management of acromegaly and hyperprolactinaemia.
Long-acting agents provide better therapeutic options and improve patient quality of life by addressing associated risks.

Related Experiment Videos